Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?
Loma Al-MansouriMalmaruha ArasaratnamHoward GurneyPublished in: European journal of hospital pharmacy : science and practice (2019)
A substantial proportion of patients with metastatic castration-resistant prostate cancer were able to receive more than 10 cycles of cabazitaxel without clinically relevant cumulative toxicity.